This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hofmann-Lehmann, R.
Right arrow Articles by Ruprecht, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hofmann-Lehmann, R.
Right arrow Articles by Ruprecht, R. M.

 Previous Article  |  Next Article 

Journal of Virology, August 2001, p. 7470-7480, Vol. 75, No. 16
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.16.7470-7480.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Postnatal Passive Immunization of Neonatal Macaques with a Triple Combination of Human Monoclonal Antibodies against Oral Simian-Human Immunodeficiency Virus Challenge

Regina Hofmann-Lehmann,1,2 Josef Vlasak,1 Robert A. Rasmussen,1,2 Beverly A. Smith,1,2 Timothy W. Baba,1,2,3 Vladimir Liska,1,2 Flavia Ferrantelli,1,2 David C. Montefiori,4 Harold M. McClure,5 Daniel C. Anderson,5 Bruce J. Bernacky,6 Tahir A. Rizvi,6 Russell Schmidt,6 Lori R. Hill,6 Michale E. Keeling,6 Hermann Katinger,7 Gabriela Stiegler,7 Lisa A. Cavacini,2,8 Marshall R. Posner,2,8 Ting-Chao Chou,9 Janet Andersen,10 and Ruth M. Ruprecht1,2,*

Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute,1 Department of Medicine, Harvard Medical School,2 Beth Israel-Deaconess Medical Center,8 and Harvard School of Public Health,10 Boston, Massachusetts 02115; Division of Newborn Medicine, Tufts University School of Medicine, Boston, Massachusetts 021113; Center for AIDS Research, Department of Surgery, Duke University Medical Center, Durham, North Carolina 277104; Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia 303225; University of Texas, M. D. Anderson Cancer Center, Bastrop, Texas 786026; Institute of Applied Microbiology, University of Agriculture, A-1190 Vienna, Austria7; and Molecular Pharmacology and Therapeutics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 100219

Received 20 February 2001/Accepted 24 May 2001

To develop prophylaxis against mother-to-child human immunodeficiency virus (HIV) transmission, we established a simian-human immunodeficiency virus (SHIV) infection model in neonatal macaques that mimics intrapartum mucosal virus exposure (T. W. Baba et al., AIDS Res. Hum. Retroviruses 10:351-357, 1994). Using this model, neonates were protected from mucosal SHIV-vpu+ challenge by pre- and postnatal treatment with a combination of three human neutralizing monoclonal antibodies (MAbs), F105, 2G12, and 2F5 (Baba et al., Nat. Med. 6:200-206, 2000). In the present study, we used this MAb combination only postnatally, thereby significantly reducing the quantity of antibodies necessary and rendering their potential use in humans more practical. We protected two neonates with this regimen against oral SHIV-vpu+ challenge, while four untreated control animals became persistently infected. Thus, synergistic MAbs protect when used as immunoprophylaxis without the prenatal dose. We then determined in vitro the optimal MAb combination against the more pathogenic SHIV89.6P, a chimeric virus encoding env of the primary HIV89.6. Remarkably, the most potent combination included IgG1b12, which alone does not neutralize SHIV89.6P. We administered the combination of MAbs IgG1b12, 2F5, and 2G12 postnatally to four neonates. One of the four infants remained uninfected after oral challenge with SHIV89.6P, and two infants had no or a delayed CD4+ T-cell decline. In contrast, all control animals had dramatic drops in their CD4+ T cells by 2 weeks postexposure. We conclude that our triple MAb combination partially protected against mucosal challenge with the highly pathogenic SHIV89.6P. Thus, combination immunoprophylaxis with passively administered synergistic human MAbs may play a role in the clinical prevention of mother-to-infant transmission of HIV type 1.

* Corresponding author. Mailing address: Dana-Farber Cancer Institute, 44 Binney St. JFB809, Boston, MA 02115-6084. Phone: (617) 632-3719. Fax: (617) 632-3112. E-mail: ruth_ruprecht{at}dfci.harvard.edu.

Journal of Virology, August 2001, p. 7470-7480, Vol. 75, No. 16
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.16.7470-7480.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Simek, M. D., Rida, W., Priddy, F. H., Pung, P., Carrow, E., Laufer, D. S., Lehrman, J. K., Boaz, M., Tarragona-Fiol, T., Miiro, G., Birungi, J., Pozniak, A., McPhee, D. A., Manigart, O., Karita, E., Inwoley, A., Jaoko, W., DeHovitz, J., Bekker, L.-G., Pitisuttithum, P., Paris, R., Walker, L. M., Poignard, P., Wrin, T., Fast, P. E., Burton, D. R., Koff, W. C. (2009). Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm. J. Virol. 83: 7337-7348 [Abstract] [Full Text]  
  • Astronomo, R. D., Lee, H.-K., Scanlan, C. N., Pantophlet, R., Huang, C.-Y., Wilson, I. A., Blixt, O., Dwek, R. A., Wong, C.-H., Burton, D. R. (2008). A Glycoconjugate Antigen Based on the Recognition Motif of a Broadly Neutralizing Human Immunodeficiency Virus Antibody, 2G12, Is Immunogenic but Elicits Antibodies Unable To Bind to the Self Glycans of gp120. J. Virol. 82: 6359-6368 [Abstract] [Full Text]  
  • Huber, M., von Wyl, V., Ammann, C. G., Kuster, H., Stiegler, G., Katinger, H., Weber, R., Fischer, M., Stoiber, H., Gunthard, H. F., Trkola, A. (2008). Potent Human Immunodeficiency Virus-Neutralizing and Complement Lysis Activities of Antibodies Are Not Obligatorily Linked. J. Virol. 82: 3834-3842 [Abstract] [Full Text]  
  • Ramessar, K., Rademacher, T., Sack, M., Stadlmann, J., Platis, D., Stiegler, G., Labrou, N., Altmann, F., Ma, J., Stoger, E., Capell, T., Christou, P. (2008). Cost-effective production of a vaginal protein microbicide to prevent HIV transmission. Proc. Natl. Acad. Sci. USA 105: 3727-3732 [Abstract] [Full Text]  
  • Gros, L., Pelegrin, M., Michaud, H.-A., Bianco, S., Hernandez, J., Jacquet, C., Piechaczyk, M. (2008). Endogenous Cytotoxic T-Cell Response Contributes to the Long-Term Antiretroviral Protection Induced by a Short Period of Antibody-Based Immunotherapy of Neonatally Infected Mice. J. Virol. 82: 1339-1349 [Abstract] [Full Text]  
  • Mehandru, S., Vcelar, B., Wrin, T., Stiegler, G., Joos, B., Mohri, H., Boden, D., Galovich, J., Tenner-Racz, K., Racz, P., Carrington, M., Petropoulos, C., Katinger, H., Markowitz, M. (2007). Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection. J. Virol. 81: 11016-11031 [Abstract] [Full Text]  
  • Dhillon, A. K., Donners, H., Pantophlet, R., Johnson, W. E., Decker, J. M., Shaw, G. M., Lee, F.-H., Richman, D. D., Doms, R. W., Vanham, G., Burton, D. R. (2007). Dissecting the Neutralizing Antibody Specificities of Broadly Neutralizing Sera from Human Immunodeficiency Virus Type 1-Infected Donors. J. Virol. 81: 6548-6562 [Abstract] [Full Text]  
  • Forthal, D. N., Gilbert, P. B., Landucci, G., Phan, T. (2007). Recombinant gp120 Vaccine-Induced Antibodies Inhibit Clinical Strains of HIV-1 in the Presence of Fc Receptor-Bearing Effector Cells and Correlate Inversely with HIV Infection Rate. J. Immunol. 178: 6596-6603 [Abstract] [Full Text]  
  • Derby, N. R., Kraft, Z., Kan, E., Crooks, E. T., Barnett, S. W., Srivastava, I. K., Binley, J. M., Stamatatos, L. (2006). Antibody Responses Elicited in Macaques Immunized with Human Immunodeficiency Virus Type 1 (HIV-1) SF162-Derived gp140 Envelope Immunogens: Comparison with Those Elicited during Homologous Simian/Human Immunodeficiency Virus SHIVSF162P4 and Heterologous HIV-1 Infection.. J. Virol. 80: 8745-8762 [Abstract] [Full Text]  
  • Forthal, D. N., Landucci, G., Cole, K. S., Marthas, M., Becerra, J. C., Van Rompay, K. (2006). Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells.. J. Virol. 80: 9217-9225 [Abstract] [Full Text]  
  • Chou, T.-C. (2006). Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacol. Rev. 58: 621-681 [Abstract] [Full Text]  
  • Dickover, R., Garratty, E., Yusim, K., Miller, C., Korber, B., Bryson, Y. (2006). Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants.. J. Virol. 80: 6525-6533 [Abstract] [Full Text]  
  • Wu, X., Parast, A. B., Richardson, B. A., Nduati, R., John-Stewart, G., Mbori-Ngacha, D., Rainwater, S. M. J., Overbaugh, J. (2006). Neutralization Escape Variants of Human Immunodeficiency Virus Type 1 Are Transmitted from Mother to Infant. J. Virol. 80: 835-844 [Abstract] [Full Text]  
  • Keck, Z.-Y., Li, T.-K., Xia, J., Bartosch, B., Cosset, F.-L., Dubuisson, J., Foung, S. K. H. (2005). Analysis of a Highly Flexible Conformational Immunogenic Domain A in Hepatitis C Virus E2. J. Virol. 79: 13199-13208 [Abstract] [Full Text]  
  • Forsell, M. N. E., Li, Y., Sundback, M., Svehla, K., Liljestrom, P., Mascola, J. R., Wyatt, R., Hedestam, G. B. K. (2005). Biochemical and Immunogenic Characterization of Soluble Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Expressed by Semliki Forest Virus. J. Virol. 79: 10902-10914 [Abstract] [Full Text]  
  • Gros, L., Dreja, H., Fiser, A. L., Plays, M., Pelegrin, M., Piechaczyk, M. (2005). Induction of Long-Term Protective Antiviral Endogenous Immune Response by Short Neutralizing Monoclonal Antibody Treatment. J. Virol. 79: 6272-6280 [Abstract] [Full Text]  
  • Forthal, D. N., Landucci, G., Phan, T. B., Becerra, J. (2005). Interactions between Natural Killer Cells and Antibody Fc Result in Enhanced Antibody Neutralization of Human Immunodeficiency Virus Type 1. J. Virol. 79: 2042-2049 [Abstract] [Full Text]  
  • Chenine, A.-L., Ferrantelli, F., Hofmann-Lehmann, R., Vangel, M. G., McClure, H. M., Ruprecht, R. M. (2005). Older Rhesus Macaque Infants Are More Susceptible to Oral Infection with Simian-Human Immunodeficiency Virus 89.6P than Neonates. J. Virol. 79: 1333-1336 [Abstract] [Full Text]  
  • Jiang, J. Q., Patrick, A., Moss, R. B., Rosenthal, K. L. (2005). CD8+ T-Cell-Mediated Cross-Clade Protection in the Genital Tract following Intranasal Immunization with Inactivated Human Immunodeficiency Virus Antigen Plus CpG Oligodeoxynucleotides. J. Virol. 79: 393-400 [Abstract] [Full Text]  
  • Mehandru, S., Wrin, T., Galovich, J., Stiegler, G., Vcelar, B., Hurley, A., Hogan, C., Vasan, S., Katinger, H., Petropoulos, C. J., Markowitz, M. (2004). Neutralization Profiles of Newly Transmitted Human Immunodeficiency Virus Type 1 by Monoclonal Antibodies 2G12, 2F5, and 4E10. J. Virol. 78: 14039-14042 [Abstract] [Full Text]  
  • Zhang, H., Huang, Y., Fayad, R., Spear, G. T., Qiao, L. (2004). Induction of Mucosal and Systemic Neutralizing Antibodies against Human Immunodeficiency Virus Type 1 (HIV-1) by Oral Immunization with Bovine Papillomavirus-HIV-1 gp41 Chimeric Virus-Like Particles. J. Virol. 78: 8342-8348 [Abstract] [Full Text]  
  • Patterson, L. J., Malkevitch, N., Pinczewski, J., Venzon, D., Lou, Y., Peng, B., Munch, C., Leonard, M., Richardson, E., Aldrich, K., Kalyanaraman, V. S., Pavlakis, G. N., Robert-Guroff, M. (2003). Potent, Persistent Induction and Modulation of Cellular Immune Responses in Rhesus Macaques Primed with Ad5hr-Simian Immunodeficiency Virus (SIV) env/rev, gag, and/or nef Vaccines and Boosted with SIV gp120. J. Virol. 77: 8607-8620 [Abstract] [Full Text]  
  • Wolbank, S., Kunert, R., Stiegler, G., Katinger, H. (2003). Characterization of Human Class-Switched Polymeric (Immunoglobulin M [IgM] and IgA) Anti-Human Immunodeficiency Virus Type 1 Antibodies 2F5 and 2G12. J. Virol. 77: 4095-4103 [Abstract] [Full Text]  
  • Richman, D. D., Wrin, T., Little, S. J., Petropoulos, C. J. (2003). Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100: 4144-4149 [Abstract] [Full Text]  
  • Herrera, C., Spenlehauer, C., Fung, M. S., Burton, D. R., Beddows, S., Moore, J. P. (2002). Nonneutralizing Antibodies to the CD4-Binding Site on the gp120 Subunit of Human Immunodeficiency Virus Type 1 Do Not Interfere with the Activity of a Neutralizing Antibody against the Same Site. J. Virol. 77: 1084-1091 [Abstract] [Full Text]  
  • Pantophlet, R., Ollmann Saphire, E., Poignard, P., Parren, P. W. H. I., Wilson, I. A., Burton, D. R. (2002). Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120. J. Virol. 77: 642-658 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»